Evaluation of an electronic critical drug interaction program coupled with active pharmacist intervention

Annals of Pharmacotherapy

Volumn 41, Issue 12, 2007, Pages 1979-1985

  Humphries, Tammy L ^a,b   Carroll, Nikki ^a   Chester, Elizabeth A ^a,b,c   Magid, David ^a   Rocho, Bob ^a  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Drug interaction; Electronic monitoring program; Pharmacy intervention; Physician collaboration

Indexed keywords

CARBAMAZEPINE; CIMETIDINE; CIPROFLOXACIN; CYCLOSPORIN; FLUCONAZOLE; MACROLIDE; PHENYTOIN; THEOPHYLLINE;

ADULT; AGED; ARTICLE; CLINICAL PHARMACY; DRUG INFORMATION; DRUG MARKETING; ELECTRONICS; FEMALE; HEALTH CARE ORGANIZATION; HUMAN; INFORMATION PROCESSING; MALE; PHARMACIST; PRESCRIPTION; PRIORITY JOURNAL; RANK SUM TEST; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CLINICAL PHARMACY INFORMATION SYSTEMS; COLORADO; DRUG INTERACTIONS; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; MALE; MEDICATION ERRORS; MIDDLE AGED; PHARMACISTS;

EID: 36849062007     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K349     Document Type: Article

References (28)

1. Hartshorn EA, Tatro DS. Principles of drug interactions. In: Tatra DS, ed. Drug interaction facts, 5th ed, St. Louis; Facts and Comparisons;1996:xix.
2. Bjerrum L, Andersen M, Petersen G, Kragstrup J. Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 2003;21:153-8.
3. Jankel CA, Speedie SM. Detecting drug interactions: a review of the literature. Ann Pharmacother 1990;24:982-9.
4. Bjorkman IK, Fastbom J, Schmidt IK, Bernsten CB, the Pharmaceutical Care of the Elderly in Europe Research (PEER) Group. Drug-drug interactions in the elderly. Ann Pharmcother 2002;36:1675-81. DOI 10.1345/aph.1A484
5. Costa AJ. Potential drug interactions in an ambulatory geriatric population. Fam Pract 1991;8:234-6.
6. Bergendal L, Friberg A, Schaffrath A. Potential drug-drug interactions in 5,125 mostly elderly out-patients in Gothenburg, Sweden. Pharm World Sci 1995;17:152-7.
7. Rosholm JU, Bjerrum L, Hallas J, Worm J, Gram LF. Polypharmacy and the risk of drug-drug interactions among Danish elderly. Dan Med Bull 1998;45:210-3.
8. Peng CC, Glassman PA, Marks IR, Fowler C, Catiglione B, Good CB. Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population. J Managed Care Pharm 2003;9:513-22.
9. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997;277:301-6.
10. Roblin DW, Leape LL. Pharmacies and prevention of potentially fatal drug interactions. JAMA 1996;275:1086-7.
11. Jankel CA, Fitterman LK. Epidemiology of drug-drug interactions as cause of hospital admissions. Drug Saf 1993;9:51-9.
12. Schneitman-McIntire O, Farnen TA, Gordon N, Chan J, Toy WA. Medication misadventures resulting in emergency department visits at an HMO medical center. Am J Health Syst Pharm 1996;531:416-22.
13. Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med 1995;155:1949-56.
14. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003;289:1652-8.
15. Hamilton RA, Briceland LL, Andritz MH. Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population, Pharmacotherapy 1998;18:1112-20.
16. Monane M, Matthias DM, Nagle BA, Miriam A. Improving prescribing patterns for the elderly through an online drug utilization review intervention: a system linking the physician, pharmacist, and computer. JAMA 1998;280:1249-52.
17. Grissinger M. Optimizing the use of computer system clinical alerts. P&T 2002;27:593.
18. Chui MA, Rupp MT. Evaluation of online prospective DUR programs in community pharmacy practice. J Managed Care Pharm 2000;6:27-32.
19. Hansten PD, Horn JT. Drug interactions. Analysis and management. St. Louis, MO: Wolters Kluwer Health;2005:1-1015.
20. Tatro DS. Drug interaction facts. St. Louis, MO: Wolters Kluwer Health, 2006:1-776.
21. Micromedex Healthcare Series. Micromedex Web Site. www.thomsonhc.com/hsc/ librarian (accessed 2006 Nov 9).
22. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002;27:299-309.
23. Matowe LK, Leister CA, Crivera C, Korth-Bradley JM. Interrupted time series analysis in clinical research. Ann Pharmacother 2003;37:1110-6. DOI 10.1345/aph.1A109
24. England E. How interrupted time series analysis can evaluate guideline implementation. Pharm J 2005;275: 344-7.
25. SAS Institute Inc. 2006. SAS OnlineDoc 9.1.3. Cary, NC: SAS Institute Inc.
26. Zhang F, Wagner A, Soumerai SB, Ross-Degnan D. Estimating confidence intervals around relative changes in outcomes in segmented regression analyses of time series data. Proceedings of the Fifteenth Annual North East SAS User Group Conference, 2002.
27. Weideman RA, Bernstein IH, McKinney WP. Pharmacist recognition of potential drug interactions. Am J Health Syst Pharm 1999;56:1524-9.
28. vanRoon EN, Flikweert S, le Comte M, et al. Clinical relevance of drug-drug interactions. Drug Saf 2005;28:1131-9.